Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Avisol Capital Partners
Investing Group Leader

Summary

  • Viridian's phase 1/2 data was better than blockbuster competitor drug Tepezza's data.
  • The company is well-funded.
  • Their strategy to capture markets still untapped by Tepezza is sound.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Digital Eye Wave Lines Stock Background

Sharamand/iStock via Getty Images

Note: This article was originally published for Marketplace subscribers on September 2, 2022.

Viridian Therapeutics (NASDAQ:VRDN) was formerly Miragen, a notoriously laggard stock I covered a few years ago. In 2020, Miragen acquired Viridian for its IGF-1R signaling

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-


Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 



This article was written by

Avisol Capital Partners
18.25K Followers

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in VRDN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About VRDN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on VRDN

Related Stocks

SymbolLast Price% Chg
VRDN
--
Compare

Trending Analysis

Trending News